Carl Schmid and Frank J. Palella, MD, review unmet needs for the uptake of HIV PrEP therapy for at-risk patient populations. Ryan Haumschild, PharmD, MS, MBA: Carl, which groups of eligible patients ...

Frank J. Palella, MD, and Ryan Bitton, PharmD, MBA, provide insight on the typical patient journey for someone who is going to receive HIV PrEP therapy and the recent increase in use of the therapy.

Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack up. It has been almost 30 years since ex-US ...

The federal government may have contributed far more to the development of HIV pre-exposure prophylaxis (PrEP) than previously estimated, researchers reported. While previous estimates said the ...

Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV ...